Urokinase plasminogen activator released by alveolar epithelial cells modulates alveolar epithelial repair in vitro.
Intra-alveolar fibrin is formed following lung injury and inflammation and may contribute to the development of pulmonary fibrosis. Fibrin turnover is altered in patients with pulmonary fibrosis, resulting in intra-alveolar fibrin accumulation, mainly due to decreased fibrinolysis. Alveolar type II epithelial cells (AEC) repair the injured alveolar epithelium by migrating over the provisional fibrin matrix. We hypothesized that repairing alveolar epithelial cells modulate the underlying fibrin matrix by release of fibrinolytic activity, and that the degree of fibrinolysis modulates alveolar epithelial repair on fibrin. To test this hypothesis we studied alveolar epithelial wound repair in vitro using a modified epithelial wound repair model with human A549 alveolar epithelial cells cultured on a fibrin matrix. In presence of the inflammatory cytokine interleukin-1beta, wounds increase by 800% in 24 hours mainly due to detachment of the cells, whereas in serum-free medium wound areas decreases by 22.4 +/- 5.2% (p < 0.01). Increased levels of D-dimer, FDP and uPA in the cell supernatant of IL-1beta-stimulated A549 epithelial cells indicate activation of fibrinolysis by activation of the plasmin system. In presence of low concentrations of fibrinolysis inhibitors, including specific blocking anti-uPA antibodies, alveolar epithelial repair in vitro was improved, whereas in presence of high concentrations of fibrinolysis inhibitors, a decrease was observed mainly due to decreased spreading and migration of cells. These findings suggest the existence of a fibrinolytic optimum at which alveolar epithelial repair in vitro is most efficient. In conclusion, uPA released by AEC alters alveolar epithelial repair in vitro by modulating the underlying fibrin matrix.
Van Leer
Coretta
C
Division of Pulmonary Medicine, University Hospital, Bern, Switzerland.
Stutz
Monika
M
Haeberli
André
A
Geiser
Thomas
T
D000906:Antibodies; D000933:Antifibrinolytic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002465:Cell Movement; D048430:Cell Shape; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology*; D005337:Fibrin / Q000378:metabolism; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000201:enzymology*; D011658:Pulmonary Fibrosis / Q000201:enzymology; D013997:Time Factors; D014148:Tranexamic Acid / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000276:immunology / Q000378:metabolism*; D014945:Wound Healing / Q000187:drug effects*; D000979:alpha-2-Antiplasmin / Q000494:pharmacology
D000906:Antibodies; D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D007375:Interleukin-1; D000979:alpha-2-Antiplasmin; C036309:fibrin fragment D; D014148:Tranexamic Acid; D005337:Fibrin; D014568:Urokinase-Type Plasminogen Activator